Estimo, Wilbert P.

HRN: 24-70-14  Sex: Male

Patient Encounter


Audit Details

Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
03/22/2024
CO-AMOXICLAV 625MG (TAB)
03/22/2024
03/29/2024
PO
625mg
Q8H
Multiple Abrasions, Face
Waiting Final Action 

Indication:  Empiric    Type of Infection:  Skin & Soft Tissue    Compliance to guidelines: Compliant To Guidelines

Initial appropriateness: Yes   

Final appropriateness: Yes   

Overall appropriateness: Yes 

Intervention



Type of Intervention done:

                    

           


Acceptance: